Has Triumeq been launched yet

Suimeikai (Triumeq) is a AIDS compound preparation developed by GlaxoSmithKline, which contains three antiretroviral drugs: Dotiravir, Abacavir...

Trelagliptin market launch date

Trelagliptin, as the world's first weekly oral DPP-4 inhibitor, has been on the market for different periods of time depending on the country a...

When should I eat Trelagliptin

As a long-acting DPP-4 inhibitor, the duration of administration of Trelagliptin has a significant impact on the efficacy of the drug. This m...

When will Trelagliptin be launched in China

As an antidiabetic drug of DPP-4 inhibitor, the marketing of Tregliptin in China is the focus of attention of diabetes patients. According to t...

When do you eat Trelagliptin

Trelagliptin, as a long-acting DPP-4 inhibitor, has the characteristics of both fixed and flexible medication time. It is necessary to arrange ...

What medicine is Trelagliptin

Treagliptin is a long-acting dipeptidyl peptidase-4 (DPP-4) inhibitor, which is mainly used for the treatment of type 2 diabetes. It has the co...

Trelagliptin usage guide

Tregliptin is a long-acting DPP-4 inhibitor, which is used for the treatment of type 2 diabetes. It is necessary to pay attention to the key in...

Larotrectinib has been launched in China and is suitable for NTRK gene fusion positive solid tumor patients. The product name is "Vitrakvi" and...

Larotrectinib, as a broad-spectrum anti-cancer targeted drug with NTRK gene fusion positivity, has been clinically studied to have significant ...

Larotrectinib has been launched in China and is suitable for solid tumor patients with NTRK gene fusion positivity. When using it, attention sh...